Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has issued a correction disclosure extending the disclosure postponement period for the contract period until after December 31, 2026, at the customer’s request regarding the contract manufacturing agreement with Ichnos Sciences originally disclosed on June 1, 2018.
📊 [Key Disclosure Details & Financial Figures]
- Original Filing & Submission Date: Single Sales and Supply Contract (Voluntary Disclosure) (Submitted on June 1, 2018)
- Reason for Correction: Extension of disclosure postponement period at the customer’s request
- Key Correction Item:
- Other Important Matters (Contract Period Disclosure Postponement Period): (Before) To be disclosed after December 31, 2025 → (After) To be disclosed after December 31, 2026
- Contract Overview (Based on Original Filing & Subsequent Amendments):
- Contract Category & Details: Other Sales and Supply Contract (Pharmaceutical Contract Manufacturing Agreement)
- Contract Amount: KRW 16,250,627,156 (USD 15,097,201 / Applied exchange rate KRW 1,076.40 per USD)
- Recent Annual Revenue: KRW 464,629,334,143 (Based on FY2017 separate financial statements)
- Contract Amount to Revenue Ratio: 3.50%
- Counterparty: Ichnos Sciences
- Contract Period Start Date: September 5, 2017
- Contract Date: June 1, 2018
- Other Important Investment Details:
- This contract reflects additional production quantities signed on November 5, 2019, following the main contract disclosed on June 1, 2018 (a follow-up to the ‘Major Management Matters’ disclosed on September 6, 2017).
- The company signed a Master Service Agreement applicable to multiple products, and this disclosure covers the first product contract under the agreement.
- If the customer succeeds in developing the contracted product, the minimum guaranteed contract amount may increase to USD 66,442,601, with potential further increases upon mutual agreement if customer demand grows.
- The contract period is slated for disclosure after December 31, 2026, due to business confidentiality.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Disclosure Timeline and Contract Updates Following Postponement Extension
This correction disclosure extends the confidentiality postponement period for the contract period with Ichnos Sciences by one year, moving the disclosure date to after December 31, 2026.
Monitoring the adjusted disclosure timeline and potential minimum guaranteed amount increases tied to the successful development of the contracted product is crucial for understanding the ongoing progress of this manufacturing deal.
Relevant developments can be verified following the extended postponement date (after December 31, 2026) or through subsequent correction disclosures and periodic reports.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
